Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Consolidated Statements of Comprehensive Loss

v3.25.1
Consolidated Statements of Comprehensive Loss - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Expenses      
Research and development $ 183,830 $ 2,418,715 $ 6,761,818
Consulting, wages and benefits 1,055,247 1,037,558 885,460
Directors' fees 168,143 179,406 122,572
Investor relations 1,360,170 919,490 928,424
Professional fees 616,859 514,263 454,071
General and administrative 320,949 375,505 448,824
Public company costs 141,404 170,184 120,813
Travel 31,916 170,187 22,538
Amortization of property and equipment 86,204 73,062 41,069
Amortization of intangible assets 31,070 66,632 17,077
Share-based payments 122,527 120,984 487,940
Loss before other items (4,118,319) (6,045,986) (10,290,606)
Fair value adjustment on derivative warrant liability 1,035,105 3,641,403 3,396,137
Foreign exchange loss (73,009) (7,025) (1,546)
Interest income 121,908 253,543 103,589
Transaction costs on derivative warrant liability (279,031)   (926,456)
Net loss for the year (3,313,346) (2,158,065) (7,718,882)
Items that may be subsequently reclassified to profit or loss:      
Currency translation differences     (128,145)
Total loss and comprehensive loss for the year $ (3,313,346) $ (2,158,065) $ (7,847,027)
Basic and diluted loss per common share      
Basic loss per common share $ (1.15) $ (1.09) $ (5.22)
Diluted loss per common share $ (1.15) $ (1.09) $ (5.22)
Weighted average number of common shares outstanding      
Weighted average number of common shares outstanding, Basic 2,878,514 1,981,734 1,479,914
Weighted average number of common shares outstanding, Diluted 2,878,514 1,981,734 1,479,914